These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11916367)

  • 1. Optimizing the prescription of statins after an acute coronary syndrome: the influence of coronary angioplasty and total cholesterol levels.
    Ferrières J; Danchin N; Grenier O; Cantet C; Thomas D; Cambou JP
    Cardiovasc Drugs Ther; 2001 Nov; 15(6):559-60. PubMed ID: 11916367
    [No Abstract]   [Full Text] [Related]  

  • 2. Status of secondary prevention in patients undergoing coronary revascularization.
    Allen JK; Blumenthal RS; Margolis S; Young DR
    Am J Cardiol; 2001 May; 87(10):1203-6: A7. PubMed ID: 11356400
    [No Abstract]   [Full Text] [Related]  

  • 3. Reperfusion for acute myocardial infarction: is the future in plastics?
    Rao SV; Jollis JG
    Mayo Clin Proc; 2000 Oct; 75(10):991-3. PubMed ID: 11040845
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated guidelines for percutaneous coronary intervention: what are the most important changes?
    Spencer BK; Smith SC
    Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of hyperlipidaemia after coronary revascularisation: follow up study.
    Delacrétaz E; Michalopoulos PG; Ruiz J; Saner H; Meier B
    BMJ; 1998 May; 316(7143):1499. PubMed ID: 9582137
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.
    Sanal S; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 Nov; 58(11):1046-8. PubMed ID: 14630888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summaries for patients. Risk factors and treatment in women with coronary artery disease.
    Ann Intern Med; 2003 Jan; 138(2):I10. PubMed ID: 12529114
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute coronary syndromes and diabetes mellitus.
    Trichon BH; Roe MT
    Diab Vasc Dis Res; 2004 May; 1(1):23-32. PubMed ID: 16305052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stable ischemic coronary disease--medical therapy or PCI?].
    Mickley H; Egstrup K
    Ugeskr Laeger; 2007 Jun; 169(23):2227. PubMed ID: 17607849
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
    Steg PG; Iung B; Feldman LJ; Cokkinos D; Deckers J; Fox KA; Keil U; Maggioni AP
    Heart; 2002 Jul; 88(1):20-4. PubMed ID: 12067934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
    Charpentier G; Puel J; Steg PG
    Presse Med; 2005 Oct; 34(18):1295-8. PubMed ID: 16269992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of acute coronary syndromes.
    Schulman SP; Fessler HE
    Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
    [No Abstract]   [Full Text] [Related]  

  • 14. [Screening and management of coronary artery disease in diabetic patients].
    Kraiem S; Abassi C; Annabi N; Smaali I; Issaa I; Wali M; Malou M; Hannachi S; Longo S; Battikh K; Slimane ML
    Tunis Med; 2006 Oct; 84(10):670-6. PubMed ID: 17193866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
    EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events
    Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National service framework for coronary heart disease. Ambiguities need to be clarified.
    Lloyd-Mostyn R
    BMJ; 2000 Sep; 321(7261):634. PubMed ID: 11023318
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators.
    Eisenberg MJ; Califf RM; Cohen EA; Adelman AG; Mark DB; Topol EJ
    Am J Cardiol; 1997 Apr; 79(7):867-72. PubMed ID: 9104896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing established coronary heart disease.
    Moher M; Schofield T; Weston S; Fullard E
    BMJ; 1997 Jul; 315(7100):69-70. PubMed ID: 9240033
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: How should stable coronary artery disease be managed in the modern era?
    Harper RW; Briganti EM; Forge BH
    Med J Aust; 2008 Jan; 188(2):122-3; author reply 123. PubMed ID: 18205592
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal medical therapy with or without PCI for stable coronary disease.
    Boden WE; O'Rourke RA; Teo KK; Hartigan PM; Maron DJ; Kostuk WJ; Knudtson M; Dada M; Casperson P; Harris CL; Chaitman BR; Shaw L; Gosselin G; Nawaz S; Title LM; Gau G; Blaustein AS; Booth DC; Bates ER; Spertus JA; Berman DS; Mancini GB; Weintraub WS;
    N Engl J Med; 2007 Apr; 356(15):1503-16. PubMed ID: 17387127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.